HC Wainwright Reduces Earnings Estimates for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Xeris Biopharma in a research note issued to investors on Friday, August 7th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2026 earnings at $0.00 EPS and FY2027 earnings at $0.11 EPS.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%.

A number of other brokerages have also issued reports on XERS. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $7.99 on Monday. The business has a 50 day moving average price of $7.72 and a 200 day moving average price of $6.80. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -72.64 and a beta of 0.66. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $10.08.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.02, for a total value of $120,300.00. Following the sale, the insider owned 1,676,126 shares of the company’s stock, valued at $13,442,530.52. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares of the company’s stock, valued at $11,638,771.56. This trade represents a 1.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 266,499 shares of company stock worth $1,996,417 in the last 90 days. 4.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds have recently modified their holdings of XERS. BlackRock Inc. bought a new position in shares of Xeris Biopharma during the second quarter valued at $115,042,000. UBS Group AG grew its holdings in shares of Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after purchasing an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd increased its position in shares of Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.